



Company Overview

Avalon GloboCare Corp. (NASDAQ: AVCO) is a global intelligent biotech developer and healthcare service provider dedicated to advancing cell-based technologies and therapeutics, with a focus on developing and empowering innovative and transformative cell-based technologies and their clinical applications. In addition, Avalon provides strategic advisory and outsourcing services to facilitate and enhance its clients' growth, development, as well as competitiveness in both the domestic and global healthcare markets. Through its subsidiaries, namely GenExosome Technologies Inc. and Avactis Biosciences Inc., Avalon is establishing a leading role in the fields of exosome-based diagnostics, cellular immunotherapy (including CAR-T/CAR-NK), and regenerative medicine.

Avalon GloboCare to Present at the Benzinga Healthcare Small Cap Conference on September 30th

Sep 23 2021, 9:00 AM EDT

UPMC and Pitt Develop New Cancer Immunotherapy with Avalon GloboCare

Aug 4 2021, 9:00 AM EDT

Avalon GloboCare Announces its Planned Acquisition Target, SenlangBio, has Initiated First-In-Human Clinical Trial in Recurrent Brain Cancer

Jul 1 2021, 9:00 AM EDT

Stock Overview

Symbol	AVCO
Exchange	Nasdaq
Market Cap	
Last Price	\$
52-Week	\$ - \$

Investor Relations

Crescendo Communications, LLC
T: (212) 671-1020
avco@crescendo-ir.com

Management Team

David Jin

Chief Executive Officer, President and Director

Meng Li

Chief Operating Officer, Secretary and Director

Luisa Ingargiola

Chief Financial Officer

Avalon GloboCare Corp.

4400 Route 9 South
Suite 3100
Freehold, NJ 07728

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.